Editorial note
COVID-19 and cardiovascular comorbidities: An update
COVID-19 e comorbilidades cardiovasculares: uma atualização
a Serviço de Cardiologia, Hospital Geral, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
b Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal
c Serviço de Cardiologia, Hospital Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal
d Faculdade de Medicina da Universidade do Porto, Porto, Portugal
e Centro Cardiovascular, Hospital dos Lusíadas, Lisboa, Portugal
f Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
Read
3104
Timeswas read the article
1288
Total PDF
1816
Total HTML
Share statistics
array:22 [ "pii" => "S2174204920303056" "issn" => "21742049" "doi" => "10.1016/j.repce.2020.06.002" "estado" => "S300" "fechaPublicacion" => "2020-08-01" "aid" => "1573" "copyrightAnyo" => "2020" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "edi" "cita" => "Rev Port Cardiol. 2020;39:417-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S217420492030310X" "issn" => "21742049" "doi" => "10.1016/j.repce.2019.09.011" "estado" => "S300" "fechaPublicacion" => "2020-08-01" "aid" => "1578" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Cardiol. 2020;39:421-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "12-month clinical outcomes after Magmaris percutaneous coronary intervention in a real-world cohort of patients: Results from the CardioHULA registry" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "421" "paginaFinal" => "425" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Resultados clínicos a 12 meses após ICP com Magmaris numa coorte de doentes do mundo real: resultados do registo CardioHULA" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Rosa A. Abellas-Sequeiros, Raymundo Ocaranza-Sanchez, Jeremias Bayon-Lorenzo, Melisa Santas-Alvarez, Carlos Gonzalez-Juanatey" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Rosa A." "apellidos" => "Abellas-Sequeiros" ] 1 => array:2 [ "nombre" => "Raymundo" "apellidos" => "Ocaranza-Sanchez" ] 2 => array:2 [ "nombre" => "Jeremias" "apellidos" => "Bayon-Lorenzo" ] 3 => array:2 [ "nombre" => "Melisa" "apellidos" => "Santas-Alvarez" ] 4 => array:2 [ "nombre" => "Carlos" "apellidos" => "Gonzalez-Juanatey" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217420492030310X?idApp=UINPBA00004E" "url" => "/21742049/0000003900000008/v1_202012171044/S217420492030310X/v1_202012171044/en/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial note</span>" "titulo" => "COVID-19 and cardiovascular comorbidities: An update" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "417" "paginaFinal" => "419" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Rogério Teixeira, Mário Santos, Victor Gil" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Rogério" "apellidos" => "Teixeira" "email" => array:1 [ 0 => "rogeriopteixeira@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Mário" "apellidos" => "Santos" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 2 => array:3 [ "nombre" => "Victor" "apellidos" => "Gil" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "Serviço de Cardiologia, Hospital Geral, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Serviço de Cardiologia, Hospital Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Faculdade de Medicina da Universidade do Porto, Porto, Portugal" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Centro Cardiovascular, Hospital dos Lusíadas, Lisboa, Portugal" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal" "etiqueta" => "f" "identificador" => "aff0030" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "COVID-19 e comorbilidades cardiovasculares: uma atualização" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">On December 8, 2019, a case of pneumonia of unknown etiology was detected in Wuhan city, Hubei province, China.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">1</span></a> On December 31, China reported a cluster of cases of pneumonia with unknown etiology to the World Health Organization (WHO), and seven days later, Chinese scientists identified the pathogen as a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">1</span></a> The WHO declared the outbreak a pandemic on 11 March 2020, due to the increasing number of cases outside China.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">2</span></a> The pandemic is spreading exponentially, with millions of people across the globe at risk of contracting coronavirus disease 2019 (COVID-19).</p><p id="par0010" class="elsevierStylePara elsevierViewall">Since January 2020 various series of COVID-19 patients have been published from China,<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">3–6</span></a> Italy<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">7</span></a> and the US.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">8</span></a> Most reports have focused on COVID-19 patients admitted to the hospital, in intensive care or in wards. The series, as expected, differ in terms of demographics, the definition of comorbidities such as chronic cardiovascular disease, and clinical outcomes. Nevertheless, some observations can be made regarding the interaction between cardiovascular comorbidities and COVID-19 infection.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Hypertension, diabetes, and cardiovascular disease were the most frequent comorbidities in infected patients requiring hospitalization, compared to other chronic diseases such as cancer, chronic kidney disease and even chronic obstructive pulmonary disease. In a meta-analysis that included six Chinese studies and 1527 COVID-19 patients, the overall prevalence of hypertension, cardiovascular and cerebrovascular disease, and diabetes were 17.1%, 16.4% and 9.7%, respectively.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">9</span></a> More recent studies from Italy<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">7</span></a> and the US<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">8</span></a> which included older patients, the majority of whom were male, report higher proportions of hypertension (over 50%) and diabetes (25%) among COVID-19 patients, which is similar to the last coronavirus pandemic, Middle East respiratory syndrome (MERS), which mainly affected the Arabian Peninsula. A systematic analysis of 637 MERS cases showed that the prevalence of hypertension and diabetes was over 50% and cardiac diseases were present in 30% of cases.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">10</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Consistently, the severity of the disease and case fatality rates have tended to be higher in COVID-19 patients with cardiovascular comorbidities. Another recent pooled analysis showed that hypertension and a history of cardiovascular disease conferred a 2.4 (95% confidence interval [CI] 1.5-3.8) and 3.4 (95% CI 1.9-6.2) times higher risk of severe COVID-19 disease, respectively.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">11</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The exact mechanisms underlying the worse prognosis of hypertensive COVID-19 patients remain unknown. One current hypothesis is that the excessive activation of the renin-angiotensin system (RAS) typical of the hypertensive patient may contribute to the progression of COVID-19 lung injury by promoting an inflammatory response (cytokine storm), smooth muscle cell contraction and vasoconstriction.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">12</span></a> Moreover, some authors speculate that the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), commonly used to treat patients with cardiovascular disease, could explain their worse outcomes.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">13</span></a> In animal studies, ACEIs/ARBs increase the expression of angiotensin-converting enzyme 2 (ACE2), the receptor which SARS-CoV-2 uses for viral entry and propagation in host cells.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">14</span></a> On the other hand, the upregulation of ACE2 expression by ACEIs/ARBs may mitigate the deleterious ACE2 downregulation associated with COVID-19 infection, conferring pulmonary (and cardiac) protection.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">15</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">At the beginning of the pandemic, all published guidelines recommended continuing ACEIs/ARBs in patients with COVID-19.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">14</span></a> In a recently published retrospective analysis of 1128 adult patients with hypertension diagnosed with COVID-19 from Hubei province, the use of ACEIs or ARBs was associated with a lower risk of both non-adjusted and adjusted all-cause mortality.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">16</span></a> Two randomized phase II clinical trials in outpatient (ClinicalTrials.gov identifier: NCT04311177) and inpatient (ClinicalTrials.gov identifier: NCT04312009) settings are currently being planned to study the effect of losartan in the context of COVID-19 infection.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">14</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">At the end of March 2020, the Centers for Disease Control and Prevention (CDC) reported data on underlying health conditions in COVID 19 patients in the US.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">17</span></a> Among 122 653 US COVID-19 cases, 7162 (5.8%) patients had data available on underlying health conditions and other potential risk factors for severe outcomes from respiratory infections, and similarly to other series, a higher proportion of patients with comorbidities were admitted to the hospital and to intensive care. On the other hand, the prevalence of common clinical conditions in the US is similar to that described in this CDC report. For example, in 2018 the prevalence of diabetes among US adults was 10.1%, similar to the COVID 19 patients (10.9%). Regarding all types of heart disease (excluding hypertension), the US prevalence in 2017 was 10.6%, comparable to that observed in the CDC data, and the findings are similar regarding chronic obstructive pulmonary disease and asthma.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">17</span></a> Moreover, data from China are also in agreement: according to the Summary of the 2018 Report on Cardiovascular Diseases in China, the prevalence of hypertension and diabetes was 23.2% and 10.9%, respectively, which is in line with the above-mentioned pooled prevalence.<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">18</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">In summary, a higher prevalence of hypertension, diabetes, and chronic heart disease compared to other chronic conditions has been reported among COVID-19 patients. The prevalence of these comorbidities may nevertheless be similar to that in the general population, and these patients may not be more susceptible to COVID-19 infection. Hypertension can function as a proxy for older age and cardiovascular and non-cardiovascular comorbidities, and hence for the association in these patients with more aggressive COVID-19 disease. There is no evidence to support the idea that ACEIs or ARBs could be harmful by increasing SARS-CoV-2 infectivity. It is as yet unknown whether the severity or level of control of underlying health conditions affects the risk for severe disease in COVID-19. Nonetheless, given the limited data and potential hazard to individual and public health, a precautionary approach should be followed by carefully protecting from infection and more closely monitoring patients with multiple comorbidities, in particular those with hypertension and cardiovascular disease.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:18 [ 0 => array:3 [ "identificador" => "bib0095" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Z. Wu" 1 => "J.M. McGoogan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "JAMA" "fecha" => "2020" "volumen" => "323" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0100" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "WHO Director-General's opening remarks at the media briefing on COVID-19: 11 March 2020" ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "Published March 11, 2020" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0105" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "X. Yang" 1 => "Y. Yu" 2 => "J. Xu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2213-2600(13)70187-5" "Revista" => array:3 [ "tituloSerie" => "Lancet Respir Med" "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24429275" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0110" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C. Huang" 1 => "Y. Wang" 2 => "X. Li" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(20)30183-5" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2020" "volumen" => "395" "paginaInicial" => "497" "paginaFinal" => "506" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31986264" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0115" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical characteristics of coronavirus disease 2019 in China" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "W. Guan" 1 => "Z. Ni" 2 => "Y. Hu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1915928" "Revista" => array:3 [ "tituloSerie" => "N Engl J Med" "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32222134" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0120" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "N. Chen" 1 => "M. Zhou" 2 => "X. Dong" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(20)30211-7" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2020" "volumen" => "395" "paginaInicial" => "507" "paginaFinal" => "513" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32007143" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0125" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "G. Grasselli" 1 => "A. Zangrillo" 2 => "A. Zanella" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.2020.5394" "Revista" => array:3 [ "tituloSerie" => "JAMA" "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9676687" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0130" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical characteristics of COVID-19 in New York City" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "P. Goyal" 1 => "J.J. Choi" 2 => "L.C. Pinheiro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMc2010419" "Revista" => array:3 [ "tituloSerie" => "N Engl J Med" "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32222134" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0135" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Li" 1 => "J. Yang" 2 => "F. Zhao" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00392-020-01626-9" "Revista" => array:6 [ "tituloSerie" => "Clin Res Cardiol" "fecha" => "2020" "volumen" => "109" "paginaInicial" => "531" "paginaFinal" => "538" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32161990" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0140" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Badawi" 1 => "S.G. Ryoo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ijid.2016.06.015" "Revista" => array:6 [ "tituloSerie" => "Int J Infect Dis" "fecha" => "2016" "volumen" => "49" "paginaInicial" => "129" "paginaFinal" => "133" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27352628" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0145" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Yang" 1 => "Y. Zheng" 2 => "X. Gou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ijid.2020.03.017" "Revista" => array:6 [ "tituloSerie" => "Int J Infect Dis" "fecha" => "2020" "volumen" => "94" "paginaInicial" => "91" "paginaFinal" => "95" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32173574" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0150" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R. Sommerstein" 1 => "M.M. Kochen" 2 => "F.H. Messerli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/JAHA.120.016509" "Revista" => array:5 [ "tituloSerie" => "J Am Heart Assoc" "fecha" => "2020" "volumen" => "9" "paginaInicial" => "e016509" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32233753" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0155" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Expert recommendations for management and treatment of cardiovascular diseases under the epidemic situation of novel coronavirus pneumonia in Hubei province" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Y. Lia" 1 => "X. Cheng" 2 => "Q. Zeng" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "J Clin Cardiol" "fecha" => "2020" "paginaInicial" => "201" "paginaFinal" => "203" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0160" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. Bavishi" 1 => "T.M. Maddox" 2 => "F.H. Messerli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamacardio.2020.1282" "Revista" => array:2 [ "tituloSerie" => "JAMA Cardiol" "fecha" => "2020" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0165" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R. Kreutz" 1 => "E.A.E.-H. Algharably" 2 => "M. Azizi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/cvr/cvaa097" "Revista" => array:3 [ "tituloSerie" => "Cardiovasc Res" "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22593200" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0170" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "P. Zhang" 1 => "L. Zhu" 2 => "J. Cai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCRESAHA.120.317134" "Revista" => array:3 [ "tituloSerie" => "Circ Res" "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7460221" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0175" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12–March 28, 2020" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "CDC COVID-19 Response Team" "etal" => true "autores" => array:3 [ 0 => "N. Chow" 1 => "K. Fleming-Dutra" 2 => "R. Gierke" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.15585/mmwr.mm6913e2" "Revista" => array:6 [ "tituloSerie" => "MMWR Morb Mortal Wkly Rep" "fecha" => "2020" "volumen" => "69" "paginaInicial" => "382" "paginaFinal" => "386" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32240123" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0180" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "China cardiovascular diseases report 2018: an updated summary" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "L.-Y. Ma" 1 => "W.-W. Chen" 2 => "R.-L. Gao" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.11909/j.issn.1671-5411.2020.01.001" "Revista" => array:6 [ "tituloSerie" => "J Geriatr Cardiol" "fecha" => "2020" "volumen" => "17" "paginaInicial" => "1" "paginaFinal" => "8" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32133031" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21742049/0000003900000008/v1_202012171044/S2174204920303056/v1_202012171044/en/main.assets" "Apartado" => array:4 [ "identificador" => "18163" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21742049/0000003900000008/v1_202012171044/S2174204920303056/v1_202012171044/en/main.pdf?idApp=UINPBA00004E&text.app=https://revportcardiol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204920303056?idApp=UINPBA00004E" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 5 | 3 | 8 |
| 2024 October | 134 | 34 | 168 |
| 2024 September | 51 | 27 | 78 |
| 2024 August | 46 | 30 | 76 |
| 2024 July | 38 | 28 | 66 |
| 2024 June | 32 | 20 | 52 |
| 2024 May | 55 | 14 | 69 |
| 2024 April | 69 | 33 | 102 |
| 2024 March | 35 | 28 | 63 |
| 2024 February | 39 | 23 | 62 |
| 2024 January | 42 | 29 | 71 |
| 2023 December | 40 | 24 | 64 |
| 2023 November | 61 | 43 | 104 |
| 2023 October | 35 | 14 | 49 |
| 2023 September | 27 | 22 | 49 |
| 2023 August | 32 | 13 | 45 |
| 2023 July | 23 | 10 | 33 |
| 2023 June | 42 | 11 | 53 |
| 2023 May | 52 | 32 | 84 |
| 2023 April | 37 | 9 | 46 |
| 2023 March | 65 | 30 | 95 |
| 2023 February | 50 | 14 | 64 |
| 2023 January | 30 | 17 | 47 |
| 2022 December | 46 | 29 | 75 |
| 2022 November | 78 | 30 | 108 |
| 2022 October | 36 | 26 | 62 |
| 2022 September | 29 | 40 | 69 |
| 2022 August | 27 | 34 | 61 |
| 2022 July | 40 | 40 | 80 |
| 2022 June | 34 | 33 | 67 |
| 2022 May | 28 | 29 | 57 |
| 2022 April | 38 | 30 | 68 |
| 2022 March | 42 | 52 | 94 |
| 2022 February | 33 | 41 | 74 |
| 2022 January | 29 | 32 | 61 |
| 2021 December | 38 | 40 | 78 |
| 2021 November | 39 | 41 | 80 |
| 2021 October | 22 | 31 | 53 |
| 2021 September | 10 | 29 | 39 |
| 2021 August | 15 | 23 | 38 |
| 2021 July | 12 | 26 | 38 |
| 2021 June | 21 | 19 | 40 |
| 2021 May | 15 | 29 | 44 |
| 2021 April | 39 | 57 | 96 |
| 2021 March | 38 | 20 | 58 |
| 2021 February | 16 | 19 | 35 |
| 2021 January | 28 | 17 | 45 |
| 2020 December | 23 | 13 | 36 |
Show all
